Impulsivity, hyperactivity, and difficulty concentrating are some of the symptoms associated with attention deficit ...
Attention-Deficit Hyperactivity Disorder, or ADHD, affects tens of millions of people in the U.S.About one in nine children ...
Pharmaceutical Technology on MSN
FDA accepts Otsuka’s centanafadine application for ADHD treatment
The Prescription Drug User Fee Act target action date for the NDA is scheduled for 24 July 2026.
The FDA has accepted Otsuka’s New Drug Application for centanafadine, a first-in-class norepinephrine, dopamine and serotonin reuptake inhibitor (NDSRI) for the treatment of attention-deficit ...
From 2022 to 2024, stimulant prescriptions issued in Connecticut increased by 13.2 percent, according to data from the state.
Seoul National University Hospital researchers have linked childhood attention-deficit/hyperactivity disorder and ...
A new, large-scale independent UK clinical trial involving 150 children and teenagers found no evidence that TNS improved ...
Difficulty focusing isn’t always ADHD. Attention problems can stem from sleep, stress, mental health, or medical factors.
For years, people thought that attention deficit hyperactivity disorder (ADHD) was a problem that only kids had. It was ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results